III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment.

A breakthrough AI system is revolutionizing cancer immunotherapy by enabling scientists to design protein-based keys that ...

Panelists discuss the critical role of patient education and multidisciplinary coordination in managing immunotherapy side ...